Company / Depreciation & Amortization
Tarsus Pharmaceuticals, Inc. Depreciation & Amortization History
FY2019-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$300.0K
FY2022
5-year range
$300.0K / $300.0K
FY2019-FY2022
Trend
-
vs FY2021
Sector context
#147 of 168
Health Care
What the data says
Tarsus Pharmaceuticals, Inc.'s depreciation & amortization of $300,000 is lower than 87% of companies in the Health Care sector (FY2022). Increased from $37,000 to $300,000 over the past 3 years.
Based on SEC 10-K filings.
$300,000 in FY2022.
Increased from $37,000 to $300,000 over the past 3 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +100.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 168This company $300.0K Sector average $212.9M
▼
-99.9% below sector average
Key checks
Key Insights
- 3-year CAGR of +100.9%, indicating consistent growth.
- Ranks #147 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $300.0K | - |
| FY2021 | - | - |
| FY2020 | $100.0K | +170.3% |
| FY2019 | $37.0K | - |
| FY2018 | - | - |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026